Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 122 entries
Sorted by: Best Match Show Resources per page
Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.

Therapeutic advances in neurological disorders

Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG.
PMID: 28450895
Ther Adv Neurol Disord. 2017 Jan;10(1):51-66. doi: 10.1177/1756285616666741. Epub 2016 Sep 02.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that is caused by an autoimmune response against central nervous system (CNS) structures. Traditionally considered a T-cell-mediated disorder, the contribution of B cells to the pathogenesis of MS has long...

Cite
Bittner S, Ruck T, Wiendl H, et al. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2016;10(1):51-66doi: 10.1177/1756285616666741.
Bittner, S., Ruck, T., Wiendl, H., Grauer, O. M., & Meuth, S. G. (2017). Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Therapeutic advances in neurological disorders, 10(1), 51-66. https://doi.org/10.1177/1756285616666741
Bittner, Stefan, et al. "Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management." Therapeutic advances in neurological disorders vol. 10,1 (2017): 51-66. doi: https://doi.org/10.1177/1756285616666741
Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017 Jan;10(1):51-66. doi: 10.1177/1756285616666741. Epub 2016 Sep 02. PMID: 28450895; PMCID: PMC5400151.
Copy Download .nbib Format: NLM
Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

OncoTargets and therapy

Hill BT, Kalaycio M.
PMID: 26366093
Onco Targets Ther. 2015 Aug 31;8:2391-7. doi: 10.2147/OTT.S68770. eCollection 2015.

Chronic lymphocytic leukemia (CLL) is a hematologic malignancy derived from a clonal population of mature B-lymphocytes characterized by relatively low CD20 antigen expression. Although the disease often takes an indolent course, the majority of patients will eventually require therapy....

Cite
Hill BT, Kalaycio M. Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia. Onco Targets Ther. 2015;8:2391-7doi: 10.2147/OTT.S68770.
Hill, B. T., & Kalaycio, M. (2015). Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia. OncoTargets and therapy, 82391-7. https://doi.org/10.2147/OTT.S68770
Hill, Brian T, and Kalaycio, Matt. "Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia." OncoTargets and therapy vol. 8 (2015): 2391-7. doi: https://doi.org/10.2147/OTT.S68770
Hill BT, Kalaycio M. Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia. Onco Targets Ther. 2015 Aug 31;8:2391-7. doi: 10.2147/OTT.S68770. eCollection 2015. PMID: 26366093; PMCID: PMC4562745.
Copy Download .nbib Format: NLM
Cost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Herring W, Pearson I, Purser M, Nakhaipour HR, Haiderali A, Wolowacz S, Jayasundara K.
PMID: 27202251
Value Health. 2014 Nov;17(7):A633. doi: 10.1016/j.jval.2014.08.2267. Epub 2014 Oct 26.

No abstract available.

Cite
Herring W, Pearson I, Purser M, et al. Cost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada. Value Health. 2014;17(7):A633doi: 10.1016/j.jval.2014.08.2267.
Herring, W., Pearson, I., Purser, M., Nakhaipour, H. R., Haiderali, A., Wolowacz, S., & Jayasundara, K. (2014). Cost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A633. https://doi.org/10.1016/j.jval.2014.08.2267
Herring, W, et al. "Cost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A633. doi: https://doi.org/10.1016/j.jval.2014.08.2267
Herring W, Pearson I, Purser M, Nakhaipour HR, Haiderali A, Wolowacz S, Jayasundara K. Cost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada. Value Health. 2014 Nov;17(7):A633. doi: 10.1016/j.jval.2014.08.2267. Epub 2014 Oct 26. PMID: 27202251.
Copy Download .nbib Format: NLM
Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling.

Iranian biomedical journal

Payandeh Z, Rajabibazl M, Mortazavi Y, Rahimpour A, Taromchi AH.
PMID: 28992681
Iran Biomed J. 2018 May 01;22(3):180-92. doi: 10.22034/ibj.22.3.180. Epub 2017 Oct 10.

BACKGROUND: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody-dependent phagocytosis...

Cite
Payandeh Z, Rajabibazl M, Mortazavi Y, et al. Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling. Iran Biomed J. 2017;22(3):180-92doi: 10.22034/ibj.22.3.180.
Payandeh, Z., Rajabibazl, M., Mortazavi, Y., Rahimpour, A., & Taromchi, A. H. (2018). Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling. Iranian biomedical journal, 22(3), 180-92. https://doi.org/10.22034/ibj.22.3.180
Payandeh, Zahra, et al. "Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling." Iranian biomedical journal vol. 22,3 (2018): 180-92. doi: https://doi.org/10.22034/ibj.22.3.180
Payandeh Z, Rajabibazl M, Mortazavi Y, Rahimpour A, Taromchi AH. Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling. Iran Biomed J. 2018 May 01;22(3):180-92. doi: 10.22034/ibj.22.3.180. Epub 2017 Oct 10. PMID: 28992681; PMCID: PMC5889503.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 18040531
Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83.

(-)-Epigallocatechin gallate, [188Re]-P2045, 12B75, 89-12; Abacavir sulfate/lamivudine, Abatacept, Abiraterone acetate, ABT-869, Adalimumab, Ad-rh Endostatin, AI-700, Alemtuzumab, Alvimopan hydrate, Amrubicin hydrochloride, AP-12009, Apomab 7.3, Arformoterol tartrate, Aripiprazole, AS-1404, Azacitidine, AZD-0530; Bevacizumab, BHT-3009, Biapenem, Bortezomib, Bosentan, Bremelanotide; CA9-SCAN, Calcitonin gene-related peptide,...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007;29(8):547-83
Bayes, M., Rabasseda, X., & Prous, J. R. (2007). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 29(8), 547-83.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 29,8 (2007): 547-83.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83. PMID: 18040531.
Copy Download .nbib Format: NLM
Role of ofatumumab in treatment of chronic lymphocytic leukemia.

Journal of blood medicine

Veliz M, Pinilla-Ibarz J.
PMID: 22287865
J Blood Med. 2011;2:71-7. doi: 10.2147/JBM.S13063. Epub 2011 May 02.

The management of chronic lymphocytic leukemia (CLL) has dramatically improved in the past decade with the addition of anti-CD20 monoclonal antibodies to the treatment armamentarium. Ofatumumab is a novel anti-CD20 monoclonal antibody recently approved in the US and Europe...

Cite
Veliz M, Pinilla-Ibarz J. Role of ofatumumab in treatment of chronic lymphocytic leukemia. J Blood Med. 2011;2:71-7doi: 10.2147/JBM.S13063.
Veliz, M., & Pinilla-Ibarz, J. (2011). Role of ofatumumab in treatment of chronic lymphocytic leukemia. Journal of blood medicine, 271-7. https://doi.org/10.2147/JBM.S13063
Veliz, Marays, and Pinilla-Ibarz, Javier. "Role of ofatumumab in treatment of chronic lymphocytic leukemia." Journal of blood medicine vol. 2 (2011): 71-7. doi: https://doi.org/10.2147/JBM.S13063
Veliz M, Pinilla-Ibarz J. Role of ofatumumab in treatment of chronic lymphocytic leukemia. J Blood Med. 2011;2:71-7. doi: 10.2147/JBM.S13063. Epub 2011 May 02. PMID: 22287865; PMCID: PMC3262343.
Copy Download .nbib Format: NLM
Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.

Therapeutic advances in hematology

Dyer MJ.
PMID: 23606931
Ther Adv Hematol. 2012 Aug;3(4):199-207. doi: 10.1177/2040620712445329.

There are now many therapeutic CD20 monoclonal antibodies undergoing clinical trials for B-cell malignancy and autoimmune conditions; which is optimal for cancer therapy is not clear. The novel human IgG1 CD20 monoclonal antibody ofatumumab has shown significant activity in...

Cite
Dyer MJ. Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. Ther Adv Hematol. 2012;3(4):199-207doi: 10.1177/2040620712445329.
Dyer, M. J. (2012). Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. Therapeutic advances in hematology, 3(4), 199-207. https://doi.org/10.1177/2040620712445329
Dyer, Martin J S. "Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia." Therapeutic advances in hematology vol. 3,4 (2012): 199-207. doi: https://doi.org/10.1177/2040620712445329
Dyer MJ. Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. Ther Adv Hematol. 2012 Aug;3(4):199-207. doi: 10.1177/2040620712445329. PMID: 23606931; PMCID: PMC3627333.
Copy Download .nbib Format: NLM
Anti-CD20 monoclonal antibodies: reviewing a revolution.

Human vaccines & immunotherapeutics

Casan JML, Wong J, Northcott MJ, Opat S.
PMID: 30096012
Hum Vaccin Immunother. 2018;14(12):2820-2841. doi: 10.1080/21645515.2018.1508624. Epub 2018 Sep 06.

Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the...

Cite
Casan JML, Wong J, Northcott MJ, et al. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018;14(12):2820-2841doi: 10.1080/21645515.2018.1508624.
Casan, J. M. L., Wong, J., Northcott, M. J., & Opat, S. (2018). Anti-CD20 monoclonal antibodies: reviewing a revolution. Human vaccines & immunotherapeutics, 14(12), 2820-2841. https://doi.org/10.1080/21645515.2018.1508624
Casan, J M L, et al. "Anti-CD20 monoclonal antibodies: reviewing a revolution." Human vaccines & immunotherapeutics vol. 14,12 (2018): 2820-2841. doi: https://doi.org/10.1080/21645515.2018.1508624
Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018;14(12):2820-2841. doi: 10.1080/21645515.2018.1508624. Epub 2018 Sep 06. PMID: 30096012; PMCID: PMC6343614.
Copy Download .nbib Format: NLM
Frontline therapies for untreated chronic lymphoid leukemia.

Experimental hematology & oncology

Liu D, Zhao J.
PMID: 31428514
Exp Hematol Oncol. 2019 Aug 17;8:15. doi: 10.1186/s40164-019-0139-8. eCollection 2019.

Therapy for chronic myeloid leukemia (CLL) is going through a major paradigm shift. Combination chemoimmunotherapy regimens have been the frontline therapies for CLL, whereas chlorambucil remained the standard frontline therapy for older patients (65 years or older) with CLL...

Cite
Liu D, Zhao J. Frontline therapies for untreated chronic lymphoid leukemia. Exp Hematol Oncol. 2019;8:15doi: 10.1186/s40164-019-0139-8.
Liu, D., & Zhao, J. (2019). Frontline therapies for untreated chronic lymphoid leukemia. Experimental hematology & oncology, 815. https://doi.org/10.1186/s40164-019-0139-8
Liu, Delong, and Zhao, Juanjuan. "Frontline therapies for untreated chronic lymphoid leukemia." Experimental hematology & oncology vol. 8 (2019): 15. doi: https://doi.org/10.1186/s40164-019-0139-8
Liu D, Zhao J. Frontline therapies for untreated chronic lymphoid leukemia. Exp Hematol Oncol. 2019 Aug 17;8:15. doi: 10.1186/s40164-019-0139-8. eCollection 2019. PMID: 31428514; PMCID: PMC6698011.
Copy Download .nbib Format: NLM
The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to .

Neural regeneration research

Guan Y, Jakimovski D, Ramanathan M, Weinstock-Guttman B, Zivadinov R.
PMID: 30539801
Neural Regen Res. 2019 Mar;14(3):373-386. doi: 10.4103/1673-5374.245462.

Multiple sclerosis (MS) is a disease of the central nervous system characterized by inflammation, demyelination, and neuronal damage. Environmental and genetic factors are associated with the risk of developing MS, but the exact cause still remains unidentified. Epstein-Barr virus...

Cite
Guan Y, Jakimovski D, Ramanathan M, et al. The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to . Neural Regen Res. 2019;14(3):373-386doi: 10.4103/1673-5374.245462.
Guan, Y., Jakimovski, D., Ramanathan, M., Weinstock-Guttman, B., & Zivadinov, R. (2019). The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to . Neural regeneration research, 14(3), 373-386. https://doi.org/10.4103/1673-5374.245462
Guan, Yi, et al. "The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to ." Neural regeneration research vol. 14,3 (2019): 373-386. doi: https://doi.org/10.4103/1673-5374.245462
Guan Y, Jakimovski D, Ramanathan M, Weinstock-Guttman B, Zivadinov R. The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to . Neural Regen Res. 2019 Mar;14(3):373-386. doi: 10.4103/1673-5374.245462. PMID: 30539801; PMCID: PMC6334604.
Copy Download .nbib Format: NLM
BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL.

Therapeutic advances in hematology

Rogers A, Woyach JA.
PMID: 32231778
Ther Adv Hematol. 2020 Mar 23;11:2040620720912990. doi: 10.1177/2040620720912990. eCollection 2020.

Older patients account for the majority of patients with chronic lymphocytic leukemia (CLL), and so strategies for managing CLL in this population is of upmost importance. Inhibition of Bruton's tyrosine kinase (BTK) has been a successful therapeutic strategy in...

Cite
Rogers A, Woyach JA. BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. Ther Adv Hematol. 2020;11:2040620720912990doi: 10.1177/2040620720912990.
Rogers, A., & Woyach, J. A. (2020). BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. Therapeutic advances in hematology, 112040620720912990. https://doi.org/10.1177/2040620720912990
Rogers, Andrew, and Woyach, Jennifer A. "BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL." Therapeutic advances in hematology vol. 11 (2020): 2040620720912990. doi: https://doi.org/10.1177/2040620720912990
Rogers A, Woyach JA. BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. Ther Adv Hematol. 2020 Mar 23;11:2040620720912990. doi: 10.1177/2040620720912990. eCollection 2020. PMID: 32231778; PMCID: PMC7092382.
Copy Download .nbib Format: NLM
Effect of ofatumumab on pregnancy, parturition, and lactation in cynomolgus monkeys.

Reproductive toxicology (Elmsford, N.Y.)

Bellot M, Luetjens CM, Bagger M, Horvath C, Sutter E, DeLise A, Brees D, Carballido JM, Pingili R, Ramanathan K, Kieseier BC, Hellwig K.
PMID: 34942355
Reprod Toxicol. 2021 Dec 21;108:28-34. doi: 10.1016/j.reprotox.2021.12.006. Epub 2021 Dec 21.

Knowledge of the impacts of the anti-CD20 monoclonal antibody ofatumumab on the developing immune system is limited. This study examined the effects of intravenous ofatumumab on pregnancy, parturition, and lactation, and on pre- and postnatal survival and development in...

Cite
Bellot M, Luetjens CM, Bagger M, et al. Effect of ofatumumab on pregnancy, parturition, and lactation in cynomolgus monkeys. Reprod Toxicol. 2021;108:28-34doi: 10.1016/j.reprotox.2021.12.006.
Bellot, M., Luetjens, C. M., Bagger, M., Horvath, C., Sutter, E., DeLise, A., Brees, D., Carballido, J. M., Pingili, R., Ramanathan, K., Kieseier, B. C., & Hellwig, K. (2021). Effect of ofatumumab on pregnancy, parturition, and lactation in cynomolgus monkeys. Reproductive toxicology (Elmsford, N.Y.), 10828-34. https://doi.org/10.1016/j.reprotox.2021.12.006
Bellot, Muriel, et al. "Effect of ofatumumab on pregnancy, parturition, and lactation in cynomolgus monkeys." Reproductive toxicology (Elmsford, N.Y.) vol. 108 (2021): 28-34. doi: https://doi.org/10.1016/j.reprotox.2021.12.006
Bellot M, Luetjens CM, Bagger M, Horvath C, Sutter E, DeLise A, Brees D, Carballido JM, Pingili R, Ramanathan K, Kieseier BC, Hellwig K. Effect of ofatumumab on pregnancy, parturition, and lactation in cynomolgus monkeys. Reprod Toxicol. 2021 Dec 21;108:28-34. doi: 10.1016/j.reprotox.2021.12.006. Epub 2021 Dec 21. PMID: 34942355.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 122 entries